# STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant

Study · id `cardio:ct-nct07007143` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07007143](<https://clinicaltrials.gov/study/NCT07007143>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07007143

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Heart failure; Valve and congenital heart disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1032 participants.

## Technical summary

Registry record NCT07007143. Randomized; no masking; primary purpose treatment. Start 2025-07-31 (actual); primary completion 2028-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1032 participants (planned count; ClinicalTrials.gov record NCT07007143, source copy `cardio:ctgov-nct07007143-2026-03-09`, retrieved 2026-10-26)
- Started: 2025-07-31 (actual) (ClinicalTrials.gov record NCT07007143, source copy `cardio:ctgov-nct07007143-2026-03-09`, retrieved 2026-10-26)
- Primary completion: 2028-09-30 (anticipated) (ClinicalTrials.gov record NCT07007143, source copy `cardio:ctgov-nct07007143-2026-03-09`, retrieved 2026-10-26)
- Completion: 2029-09-30 (anticipated) (ClinicalTrials.gov record NCT07007143, source copy `cardio:ctgov-nct07007143-2026-03-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07007143, source copy `cardio:ctgov-nct07007143-2026-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07007143-2026-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
- Acronym: STAR-TEER Ⅱ
- Condition: Mitral Regurgitation
- Intervention (Drug): Experimental: Aspirin monotherapy
- Intervention (Drug): Active Comparator: Aspirin+Clopidogrel
- Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital (`cardio:org-chinese-academy-of-medical-sciences-fuwai-hospital`)

## Provenance

Content hash: ebff7a02d48d691069c03665c0a1bcea2827d47b99c7cc3427984ba7c14588a5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
